These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 8548755

  • 1. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
    Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN.
    Cancer Res; 1996 Jan 01; 56(1):150-3. PubMed ID: 8548755
    [Abstract] [Full Text] [Related]

  • 2. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
    Ono Y, Tamiya T, Ichikawa T, Kunishio K, Matsumoto K, Furuta T, Ohmoto T, Ueki K, Louis DN.
    J Neuropathol Exp Neurol; 1996 Oct 01; 55(10):1026-31. PubMed ID: 8857999
    [Abstract] [Full Text] [Related]

  • 3. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
    Tsuzuki T, Tsunoda S, Sakaki T, Konishi N, Hiasa Y, Nakamura M.
    Cancer; 1996 Jul 15; 78(2):287-93. PubMed ID: 8674005
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
    Schultz DC, Vanderveer L, Buetow KH, Boente MP, Ozols RF, Hamilton TC, Godwin AK.
    Cancer Res; 1995 May 15; 55(10):2150-7. PubMed ID: 7743516
    [Abstract] [Full Text] [Related]

  • 11. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.
    Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff I, Schmiegel W, Baylin SB, Kern SE, Herman JG.
    Cancer Res; 1997 Aug 01; 57(15):3126-30. PubMed ID: 9242437
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Infrequent CDKN2 mutation in human differentiated thyroid cancers.
    Tung WS, Shevlin DW, Bartsch D, Norton JA, Wells SA, Goodfellow PJ.
    Mol Carcinog; 1996 Jan 01; 15(1):5-10. PubMed ID: 8561866
    [Abstract] [Full Text] [Related]

  • 14. Increased p16 levels correlate with pRb alterations in human urothelial cells.
    Yeager T, Stadler W, Belair C, Puthenveettil J, Olopade O, Reznikoff C.
    Cancer Res; 1995 Feb 01; 55(3):493-7. PubMed ID: 7834615
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
    Nakagawa K, Conrad NK, Williams JP, Johnson BE, Kelley MJ.
    Oncogene; 1995 Nov 02; 11(9):1843-51. PubMed ID: 7478613
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.